Bangkok Lab and Cosmetic PCL
SET:BLC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (14), the stock would be worth ฿-11.8 (404% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.6 | ฿3.88 |
0%
|
| Industry Average | 14 | ฿-11.8 |
-404%
|
| Country Average | 13.4 | ฿-11.36 |
-393%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
2.3B THB | -4.6 | 13.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 59.5 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 50.6 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 16.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 12.1 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 22.3 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 24.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 19.1 | 16.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 8.8 |
| Median | 13.4 |
| 70th Percentile | 20 |
| Max | 1 747 |
Other Multiples
Bangkok Lab and Cosmetic PCL
Glance View
Bangkok Lab & Cosmetic PCL engaes in the provision of pharmaceuticals and health products. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2023-06-21. The firm is engaged in the production of medicines and health products by selecting raw materials. The firm has produced more than 100 products. Its products include ZENZERA 200 SUSPENSION, ZENZERA, SYNOVAR UC40, RADIARA, PROCEMINE, FANGO-B, EMBLICOF COUGH MIXTURE, CLINIGEL STERILE, RAQUA FIBROTA, RAQUA COLLAGEN, SYNOVAR UC, SYNOVAR POWDER, NACOXIB, LUTI-BERRY MIXED, ZIGA GEL (orange), ZERTINE SYRUP, VIZO Cream, SPORAXYL CREAM, NORAPHEN, MURHINOL-250 SYRUP, NORFLOXYL 400, NOCID, MURHINOL-250 SYRUP, MUCOBROX, GYNOSTEN CREAM, and GYNOSTEN 500, AROTIKA COOL GEL, ALLERAX-FC, AROTIKA RUB LOTION (SPRAY), Calza c Dietary Supplement, Calza PLUS POWDER Dietary, and Calza-750 TAB FC, among others. Its products are distributed through Bangkok Drug Co., Ltd., Beereach (Thailand) Co., Ltd., Pharmaline Company Limited, Pharma Alliance Company Ltd., and Bangkok Medica Co., Ltd.
